Fungal Foot Infections Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the fungal foot infection pipeline landscape. It provides comprehensive information on the therapeutics under development for onychomycosis (Tinea unguium) and athlete’s foot (Tinea pedis), and key players active within these indications.

Both of these indications are fungal infections primarily affecting the feet. Onychomycosis affects the nails, whereas athlete’s foot affects the skin under the feet and between the toes. Common symptoms include discomfort, itchiness, and - in the case of onychomycosis - discoloured and disfigured nails. Combined, these infections affect around 25% of the adult population.

There is considerable overlap in both the development of pipeline products and existing marketed products between the two indications, which reflects similarities in the underlying pathophysiology. There are a total of 25 products in development for both indications, by 24 companies.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration